DALDA peptide

DALDA peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-YrFK-OH

H-Tyr-(D)Arg-Phe-Lys-OH

4

95.68%

C₃₀H₄₄N₈O₆

612.72

Synthetic

Powder

DALDA is a metabolically stable neuropeptide. DALDA has a plasma pharmacokinetic profile similar to that of sucrose. DALDA, which has a molecular weight of 616, has a log PC that is twofold greater than that of sucrose, and DALDA has a BBB PS product that is also twofold greater than that of sucrose. DALDA slowly traverses the BBB via lipid-mediated free diffusion.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Samii A, Bickel U, Stroth U, Pardridge WM. Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphin analogue. Am J Physiol. 1994 Jul;267(1 Pt 1):E124-31. doi: 10.1152/ajpendo.1994.267.1.E124. PMID: 8048500.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.